Pharmaceutical Product Development 8-K 2008
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 2, 2008
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
929 North Front Street, Wilmington, North Carolina 28401
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (910) 251-0081
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
(b) On April 2, 2008, Paul S. Covington, M.D., notified the Company that he is retiring from his position as the Executive Vice President of Development and Chief Medical Officer of PPD Development, LP, a wholly owned subsidiary of the Company effective June 30, 2008. He has agreed to continue his employment in the position of a special project advisor through January 2009 to assist on selected projects and the transition of his responsibilities.
The Company is furnishing as an exhibit to this Form 8-K a press release, dated April 3, 2008, describing Dr. Covingtons resignation.
Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.